NCT07240753Not yet recruiting
A Chinese Cohort of Cervical Large Cell Neuroendocrine Carcinoma
Clinical Characteristics and Prognostic Factors of Large Cell Neuroendocrine Carcinoma of the Cervix: A Multicenter, Bidirectional Cohort Study
Source: ClinicalTrials.gov · Last updated 21 Nov 2025
Brief summary (registry, in English)
Cervical large cell neuroendocrine carcinoma (LCNEC) exhibits highly aggressive biological behavior, including strong invasiveness, a high propensity for metastasis, drug resistance, and poor prognosis, necessitating heightened clinical and pathological awareness. This study aims to summarize the clinical characteristics of LCNEC and analyze various prognostic factors to enhance understanding and vigilance toward this disease. Combined with precise pathological diagnosis, improving diagnostic accuracy is crucial for formulating treatment strategies and assessing patient prognosis.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 15 Nov 2025
- Start date
- 1 Dec 2025
- Primary completion date
- 1 Nov 2028
- Lead sponsor
- Lili
- Diseases
- Cervical cancer, Childhood cancers
- NCT number
- NCT07240753
What you commit to
- Study type: Observational
- Planned participants: 200
- From 1 Dec 2025 to the primary completion date, 1 Nov 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \-
Who the study is looking for
- \-
Sex: Female · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.